CN117813505A - 使用了可溶型clec2的急性脑血管病的风险评价方法 - Google Patents

使用了可溶型clec2的急性脑血管病的风险评价方法 Download PDF

Info

Publication number
CN117813505A
CN117813505A CN202280038994.9A CN202280038994A CN117813505A CN 117813505 A CN117813505 A CN 117813505A CN 202280038994 A CN202280038994 A CN 202280038994A CN 117813505 A CN117813505 A CN 117813505A
Authority
CN
China
Prior art keywords
cerebrovascular disease
patient
acute cerebrovascular
concentration
cardiac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280038994.9A
Other languages
English (en)
Chinese (zh)
Inventor
和田英夫
川村雅英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN117813505A publication Critical patent/CN117813505A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
CN202280038994.9A 2021-05-31 2022-05-31 使用了可溶型clec2的急性脑血管病的风险评价方法 Pending CN117813505A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-091606 2021-05-31
JP2021091606 2021-05-31
PCT/JP2022/022076 WO2022255348A1 (ja) 2021-05-31 2022-05-31 可溶型ｃｌｅｃ２を用いた急性脳血管障害のリスク評価方法

Publications (1)

Publication Number Publication Date
CN117813505A true CN117813505A (zh) 2024-04-02

Family

ID=84323407

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280038994.9A Pending CN117813505A (zh) 2021-05-31 2022-05-31 使用了可溶型clec2的急性脑血管病的风险评价方法

Country Status (6)

Country Link
US (1) US20240264174A1 (https=)
EP (2) EP4636404A3 (https=)
JP (1) JPWO2022255348A1 (https=)
KR (1) KR20240017000A (https=)
CN (1) CN117813505A (https=)
WO (1) WO2022255348A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025075139A1 (ja) * 2023-10-06 2025-04-10 Ｐｈｃ株式会社 可溶型ｃｌｅｃ－２を用いた脳心血管・腎イベントの長期的発症ハイリスク評価法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6078845U (ja) 1983-11-04 1985-06-01 ライオン株式会社 食用廃油固化処理用具
AU2002359815A1 (en) * 2001-12-19 2003-07-09 Immunex Corporation C-type lectin polypeptide, polynucleotide and methods of making and use thereof
JP2007070359A (ja) * 2005-09-06 2007-03-22 Univ Of Yamanashi 止血疾患治療用の医薬組成物
EP2269597A1 (en) * 2009-06-22 2011-01-05 CSL Behring GmbH CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis
EP2272874A1 (en) * 2009-07-10 2011-01-12 CSL Behring GmbH Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation
JP6078845B2 (ja) * 2012-09-28 2017-02-15 株式会社Ｌｓｉメディエンス 可溶型ｃｌｅｃ−２に基づく血小板活性化測定方法
US10227407B2 (en) * 2013-10-10 2019-03-12 Yukinari Kato Anti-podoplanin antibody
JP7172286B2 (ja) 2018-08-28 2022-11-16 スズキ株式会社 ニーエアバッグ取付け構造
JP6883348B2 (ja) 2019-06-26 2021-06-09 稔 甲斐 閉塞防止機能付振動篩用網及び振動篩装置
JP7215389B2 (ja) 2019-10-08 2023-01-31 株式会社デンソー 電子制御装置
EP4113524A4 (en) * 2020-02-28 2024-03-06 LSI Medience Corporation METHOD FOR MEASURING PLATELE ACTIVATION BASED ON SOLUBLE CLEC-2 AND PLATELE COUNT

Also Published As

Publication number Publication date
EP4636404A3 (en) 2025-11-19
US20240264174A1 (en) 2024-08-08
WO2022255348A1 (ja) 2022-12-08
EP4636404A2 (en) 2025-10-22
KR20240017000A (ko) 2024-02-06
JPWO2022255348A1 (https=) 2022-12-08
EP4350349A4 (en) 2025-04-23
EP4350349A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
CN115190973B (zh) 基于可溶性clec-2与血小板数的血小板活化测定方法
JP4523587B2 (ja) Ａ型及びｂ型急性大動脈解離と急性心筋梗塞の鑑別方法及び鑑別用キット
CN117813505A (zh) 使用了可溶型clec2的急性脑血管病的风险评价方法
EP4350350A1 (en) Method for assessing risk of hemorrhagic stroke using soluble clec2
US12332252B2 (en) GFAP accumulating in stroke
JP7851566B2 (ja) 早発性子癇前症の予後についてのバイオマーカー
CN103210312A (zh) 通过软骨酸性蛋白1 检测脑梗塞的方法
HK40127498A (en) Method for evaluating risk of acute cerebral vascular disease using soluble clec2
HK40105374A (en) Method for evaluating risk of acute cerebral vascular disease using soluble clec2
RU2543653C1 (ru) Способ диагностики нарушений свертываемости крови у беременных во 2-3 триместре
JP2012107935A (ja) Ｄｅｓｍｏｇｌｅｉｎ−２蛋白質による脳梗塞の検査方法
HK40106384A (en) Method for assessing risk of hemorrhagic stroke using soluble clec2
JPWO2004111645A1 (ja) 急性大動脈解離の判定方法及び判定用試薬
JP2011237402A (ja) ガレクチン−３結合蛋白質による脳梗塞の検査方法
Alakraa et al. Comparison of Platelet Activation Phenotyping Markers, Soluble Fibrin Monomer Complex and Soluble P-Selectin in Venous Thromboembolism
WO2025075139A1 (ja) 可溶型ｃｌｅｃ－２を用いた脳心血管・腎イベントの長期的発症ハイリスク評価法
JPWO2012067150A1 (ja) Ｉｎｔｅｒｌｅｕｋｉｎ−６ｒｅｃｅｐｔｏｒｓｕｂｕｎｉｔｂｅｔａ蛋白質による脳梗塞の検査方法
JP2012107933A (ja) Ｈｅｍｏｐｅｘｉｎ蛋白質による脳梗塞の検査方法
JP2026501110A (ja) 早発性子癇前症の予後についての多重ｓｆｌｔ－１測定
JP2012107932A (ja) Ｃｌｕｓｔｅｒｉｎ蛋白質による脳梗塞の検査方法
HK40129389A (zh) 用於早发型先兆子痫预後的多个sflt-1测量值
Hsiao et al. D-dimer assay not adequate for spontaneous intracranial hemorrhage screening
JP2012107931A (ja) Ｂｃｌ−ＸＬ蛋白質による脳梗塞の検査方法
JP2015111050A (ja) Ｋａｌｌｉｓｔａｔｉｎ蛋白質による脳梗塞検査方法
JPWO2006016687A1 (ja) 破裂性腹部大動脈瘤の判定方法及び判定用試薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination